舍尼通(Cernilton) - 在研适应症：慢性前列腺炎，前列腺增生症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Cernitin、セルニルトン

靶点-

作用机制-

治疗领域

泌尿生殖系统疾病

在研适应症

慢性前列腺炎前列腺增生症

非在研适应症-

原研机构

Tobishi Pharmaceutical Co. Ltd.

在研机构

Tobishi Pharmaceutical Co. Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1968-09-05),

慢性前列腺炎前列腺增生症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与舍尼通相关的临床试验

JPRN-UMIN000027420

/ Completed临床4期IIT

Comparison of cernitin pollen extract and tadalafil in the treatment for benign prostatic hyperplasia with chronic prostatitis: A randomized, prospective study - Comparison of cernitin pollen extract and tadalafil in the treatment for chronic prostatitis

开始日期2017-07-21

申办/合作机构

Nagoya University Graduate School of Medicine

NCT00919893

/ Completed临床3期IIT

Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-chronic Pelvic Pain Syndrome

In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

开始日期1999-12-01

申办/合作机构

University of Giessen

[+1]

100 项与舍尼通相关的临床结果

登录后查看更多信息

100 项与舍尼通相关的转化医学

登录后查看更多信息

100 项与舍尼通相关的专利（医药）

登录后查看更多信息

68

项与舍尼通相关的文献（医药）

2021-02-01·Wiener klinische Wochenschrift4区 · 医学

A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia

4区 · 医学

Review

作者: Zhou, Xiaohui ; Diallo, Maladho Tanta ; Wazir, Junaid ; Ullah, Rahat ; Khan, Farhan Ullah ; Hossain, Md Amir ; Ihsan, Awais Ullah

Benign prostatic hyperplasia (BPH) is a common disease that can cause uncomfortable lower urinary tract symptoms. The occurrence of symptomatic BPH develops after the age of 40 years and increases gradually with age to reach more than 50% at the age of 60 years and severely disturbs the quality of life of the patients. Alpha-blockers and 5‑alpha reductase inhibitors are first-line agents used for the treatment of BPH. Due to the adverse effects of these conventional therapies, many patients turn to phytotherapy and other alternative therapies. This review covers alternative therapies, i.e., phytotherapy (cernilton, eviprostat, quercetin, saw palmetto and pumpkin seed) and physical therapy (acupuncture, aquablation, pulsed electromagnetic field, prostate urethral lift, radial extracorporeal shock wave therapy, thermobalancing therapy, and transurethral needle ablation) commonly used in the management of BPH.

2020-09-01·Neurourology and Urodynamics3区 · 医学

Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study

3区 · 医学

Article

作者: Ishida, Shohei ; Funahashi, Yasuhito ; Matsukawa, Yoshihisa ; Fujita, Takashi ; Tochigi, Kosuke ; Kato, Masashi ; Naito, Yushi ; Gotoh, Momokazu

AbstractAimsTo compare the efficacy of cernitin pollen extract (cernitin) or tadalafil for treating persistent chronic pelvic pain despite α1‐blocker monotherapy in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and lower urinary tract symptoms (LUTS).MethodsA total of 100 patients with refractory CP/CPPS despite ongoing α1‐blocker monotherapy were randomized to receive add‐on therapy with either cernitin (4 capsules/day) or tadalafil (5 mg/d) for 12 weeks. At week 12, changes from baseline in the patients’ CP/CPPS, LUTS, and voiding function, as assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH‐CPSI), the International Prostate Symptom Score (IPSS), and uroflowmetry, respectively, were compared between the groups.ResultsThe final analysis included 42 and 45 patients in the cernitin and tadalafil groups, respectively. Although the NIH‐CPSI total, NIH‐CPSI pain sub‐score, and NIH‐CPSI quality of life sub‐score significantly improved in both groups, the cernitin (vs tadalafil) group showed significantly greater improvements in the NIH‐CPSI total score (−6.8 vs −4.6; P = .02) and NIH‐CPSI pain sub‐score (−4.1 vs −1.5; P < .001). Half (50%) of the patients in the cernitin group showed a reduction greater than 50% in their NIH‐CPSI pain sub‐score; in the tadalafil group, only four patients (8.9%) showed ≥50% improvement (P < .001). In contrast, the improvement in LUTS was significantly superior in the tadalafil group.ConclusionBoth cernitin and tadalafil significantly ameliorated chronic pelvic pain in patients with refractory CP/CPPS. The add‐on of cernitin was more effective than tadalafil for pelvic pain and discomfort.

2020-01-01·Pharmaceutical Biology3区 · 医学

The effect of Jiedu Huoxue decoction on rat model of experimental nonbacterial prostatitis via regulation of miRNAs

3区 · 医学

ArticleOA

作者: Yan, Zhangren ; Huang, Chunhua ; Wang, Wanchun ; Wang, Jiangang ; Wu, Yunbo ; Huang, Gang ; Mao, Wenli ; Yi, Jun

CONTEXTThe underlying mechanisms of Jiedu Huoxue decoction (JDHXD) in treating chronic prostatitis have not been fully explored.OBJECTIVEThis study investigates the miRNAs as potential biomarkers and the effect of JDHXD on the rat model of experimental nonbacterial prostatitis.MATERIALS AND METHODSFifty-four Sprague-Dawley male rats were randomly divided into normal control, model, JDHXD low dose (0.5 g/kg/day), medium dose (1 g/kg/day), high dose (2 g/kg/day) and western medicine (cernilton 0.094 g/kg/day) groups, and intragastrically administered once daily for 30 days. The control and model (upon successful establishment) groups received distilled water. Differential expression of miRNAs was analysed with high-throughput miRNA sequencing and validated with qRT-PCR and Northern blot. Prediction of specific target genes and functional enrichment analysis were performed with bioinformatics.RESULTSLD₅₀ test showed no sign of toxicity with maximum feasible dose 4 g/kg JDHXD. Compared with control, 495 miRNAs showed expression changes in CAP/CPPS rats, of which 211 were significantly different and 37 were prostatic-related. There were 181 differentially expressed miRNAs between the model and high dose JDHXD groups, of which 23 were identical with the control and model groups. Compared with control, miR-146a, miR-423 and miR-205 expression increased significantly in the model group, decreased dose-dependently in the JDHXD groups (p < 0.05), and vice-versa for miR-96 (p < 0.05). The effect of low dose JDHXD was comparable to cernilton (p > 0.05).DISCUSSION AND CONCLUSIONSFuture studies may explore the contributions of the active components in JDHXD. The study design is generalisable. The effect can be repeatedly verified in clinical trials.

100 项与舍尼通相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G04C	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性前列腺炎	日本	Tobishi Pharmaceutical Co. Ltd.	1968-09-05
前列腺增生症	日本	Tobishi Pharmaceutical Co. Ltd.	1968-09-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00919893 (CTgov)	临床3期	慢性盆腔疼痛综合征 \| 慢性前列腺炎	139	Cernilton (Cernilton)	顧憲製鑰鹽夢鬱齋餘製(膚淵鏇範鹽窪顧襯夢廠) = 觸齋遞衊襯襯醖壓獵鏇醖鏇夢襯鹹築醖構鏇壓 (淵衊鏇餘獵製選簾積餘, 窪製觸鏇襯鹹繭膚糧製 ~ 獵糧醖遞鹽夢廠蓋窪網) 更多	-	2009-06-12
				Placebo (Placebo)	顧憲製鑰鹽夢鬱齋餘製(膚淵鏇範鹽窪顧襯夢廠) = 衊積網襯窪膚窪鹽願糧醖鏇夢襯鹹築醖構鏇壓 (淵衊鏇餘獵製選簾積餘, 淵選齋範繭窪選遞積蓋 ~ 鬱鑰構積蓋憲夢構膚鑰) 更多